EcoDrugPlus

Atpase H+/k+ Transporting Subunit Alpha

Ensembl ID : ENSONIG00000005974
Gene Symbol: ATP4A
1 Cross references
183 Possible Orthologues:

Atpase H+/k+ Transporting Subunit Beta

Ensembl ID : ENSONIG00000003180
Gene Symbol: ATP4B
4 Cross references
184 Possible Orthologues:

Atpase Na+/k+ Transporting Subunit Alpha 1

Ensembl ID : ENSONIG00000012456
Gene Symbol: ATP1A1
3 Cross references
181 Possible Orthologues:

Atpase Na+/k+ Transporting Subunit Beta 1

Ensembl ID : ENSONIG00000019331
Gene Symbol: ATP1B1
4 Cross references
225 Possible Orthologues:

Atpase Na+/k+ Transporting Subunit Beta 2

Ensembl ID : ENSONIG00000004231
Gene Symbol: ATP1B2
4 Cross references
203 Possible Orthologues:

Atpase Na+/k+ Transporting Subunit Beta 3

Ensembl ID : ENSONIG00000027418
Gene Symbol: ATP1B3
3 Cross references
236 Possible Orthologues:

Atr Serine/threonine Kinase

Ensembl ID : ENSONIG00000000770
Gene Symbol: ATR
3 Cross references
205 Possible Orthologues:

Axl Receptor Tyrosine Kinase

Ensembl ID : ENSONIG00000003873
Gene Symbol: AXL
3 Cross references
187 Possible Orthologues:

B-Raf Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSONIG00000032587
Gene Symbol: BRAF
3 Cross references
218 Possible Orthologues:

B2 Bradykinin Receptor-Like

Ensembl ID : ENSONIG00000001434
Gene Symbol: LOC100691077
3 Cross references
147 Possible Orthologues:

Bcl2 Like 1

Ensembl ID : ENSONIG00000001632
Gene Symbol: BCL2L1
3 Cross references
226 Possible Orthologues:

Bcr Activator Of Rhogef And Gtpase

Ensembl ID : ENSONIG00000003817
Gene Symbol: BCR
3 Cross references
205 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).